Trial · NCT01265875
Secretin Infusion for Pain Due to Chronic Pancreatitis
NCT01265875, Phase 1, Phase 2, Completed, ChiRhoClin, Inc.; results first posted 2016-03-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Secretin Infusion for Pain Due to Chronic Pancreatitis. Trials, record NCT01265875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01265875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Secretin Infusion for Pain Due to Chronic Pancreatitis
- NCT number
- NCT01265875
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- ChiRhoClin, Inc.
- Conditions
- Chronic Pancreatitis
- Interventions
- Human Secretin
- First posted
- 2010-12-23
- Last updated
- 2016-03-09
- Results first posted
- 2016-03-01
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Baseline, Days 1, 2, 3, 4, 7, 30. | 10 point visual analog scale. 0= no pain. 10= worst possible pain. Days 1, 2, 3 were infusion days that included 5 VAS scores each day. |
| Primary | Opiate Use at Baseline, Days 4 and 30. | Baseline, Day 4, Day 30. | Daily opiate use (oral morphine equivalent). |
| Primary | Quality of Life at Baseline, Day 4 and Day 30. | Baseline, Day 4, Day 30. | Sf-36 ranges from 0 to 151. Higher scores indicating worse outcomes. |
| Secondary | Number of Participants With Serious Adverse Events. | 30 Days | |
| Secondary | VAS Score at Each Administered Dose. | Days 1, 2, and 3. | 10 point scare from 0-10 with higher scores meaning higher levels of pain. VAS score assessed after each dose was summarized over Days 1, 2, and 3. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Baseline, Days 1, 2, 3, 4, 7, 30. | units on a scale | MEAN | |
| SECONDARY | Number of Participants With Serious Adverse Events. | 30 Days | participants | NUMBER | |
| PRIMARY | Opiate Use at Baseline, Days 4 and 30. | Baseline, Day 4, Day 30. | mg/day | MEAN | |
| PRIMARY | Quality of Life at Baseline, Day 4 and Day 30. | Baseline, Day 4, Day 30. | units on a scale | MEAN | |
| SECONDARY | VAS Score at Each Administered Dose. | Days 1, 2, and 3. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Baseline | 5.71 | Standard Deviation 1.45 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 1 Pre-dose | 6.04 | Standard Deviation 2.13 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 1 Dose 1 (.05mcg/kg) 100min post dose | 4.92 | Standard Deviation 2.20 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 1 Dose 2 (.1mcg/kg) 100 min post dose | 4.87 | Standard Deviation 2.06 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 1 Dose 3 (.2mcg/kg) 100 min post dose | 5.30 | Standard Deviation 2.19 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 1 Dose 3 (.2mcg/kg) 380 min post dose | 4.64 | Standard Deviation 2.68 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 2 Pre-dose | 5.33 | Standard Deviation 2.30 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 2 Dose 1 (.1mcg/kg) 100min post dose | 5.25 | Standard Deviation 1.88 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 2 Dose 2 (.2mcg/kg) 100min post dose | 5.50 | Standard Deviation 1.71 | units on a scale |
| VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. | Human Secretin | Day 2 Dose 3 (.4mcg/kg) 100min post dose | 4.67 | Standard Deviation 2.32 | units on a scale |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Human Secretin | 12 | |
| Overall Study | COMPLETED | Human Secretin | 11 | |
| Overall Study | NOT COMPLETED | Human Secretin | 1 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea, mild | Gastrointestinal disorders | Human Secretin | 4 | 12 | |
| other | mild flushing, upper body | Vascular disorders | Human Secretin | 6 | 12 | |
| serious | Central line infection (coagulase negative S. Aureus infection with bacteremia) | Infections and infestations | Human Secretin | 1 | 1 | 1 |
| serious | Pain, nausea, vomitting | Gastrointestinal disorders | Human Secretin | 1 | 12 | 1 |
| serious | epigastrium and right upper quadrant pain | Gastrointestinal disorders | Human Secretin | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Human Secretin | ||
| Total, other adverse events | Human Secretin | 9 | 12 |
| Total, serious adverse events | Human Secretin | 3 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23548879 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01265875
GET https://conductscience.org/api/trials/v1/NCT01265875/results?page=2